Mumbai: Indira IVF ties up with Presagen to roll out the latest Artificial Intelligence (AI) tool ‘Life Whisperer’ at their 100+ clinics across the country. This AI tool aids in improving embryo selection in in-vitro fertilisation (IVF) and provides increase in pregnancy prediction thus, reducing the number of cycles required for successful conception.
Internationally tested, Life Whisperer uses AI to assess two embryo quality metrics, Life Whisperer Viability, to assess how likely an embryo is to lead to a pregnancy, and Life Whisperer Genetics to non-invasively assesses embryo genetic integrity.
Speaking on the development, Dr Nitiz Murdia, Co-Founder and Managing Director, Indira IVF, said, “With Life Whisperer, we will be able to provide additional transparency and confidence to our patients around the IVF procedure by providing them a report on the AI results of their embryos. With the aim of improving IVF outcomes for patients in India, our organisation will continue to address every gap in the path of quality fertility treatment in the country.”
Dr Kshitiz Murdia, Co-founder and CEO, Indira IVF, said, “We are delighted to be able to include this new technology which will certainly enhance the success rate of IVF procedures. Life Whisperer will support embryologists in making an objective decision on the best embryo required for conception. It will ensure couples have the greatest chance of starting a new family sooner.”
Commenting on the pact, Dr Michelle Perugini, CEO, Presagen, said, “We are thrilled to be working with Indira IVF in helping them integrate the most technically advanced and well-tested AI technology into their IVF treatment procedures. Indira IVF and Presagen have a long-term partnership to continue in furthering the advancement of AI in fertility.”
Life Whisperer is currently authorised for sale in over 40 countries worldwide, with India as a key market. It is backed by extensive scientific evidence, clinical data, and numerous recent publications, including two in Nature Scientific Reports, two in Human Reproduction, and a recent paper in Reproductive Biomedicine Online (RBMO), and is regularly presented at global fertility meetings conducted by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM).